The recent funding round, totaling $330 million, will enable the startup to advance its late-stage testing efforts for eye disease treatments.
Investor interest in ophthalmology ventures appears to be robust, reflecting a growing focus on innovations in eye health.
As the startup prepares for these critical testing phases, it aims to make significant contributions to the field of eye disease treatment.
Updates
Update at 11:00 UTC on 2026-06-24
STAT reported A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Sources: STAT